Healthcare
Live Price
Offline$15.01
+0.00% today
Window Change
+0.94%
Window
Jun 23, 2025 → Jul 21, 2025
Historical coverage is still filling in
This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.
Coverage: 20 bars · Jun 23, 2025 → Jul 21, 2025
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Biotage AB (publ) (BITGF) is a Healthcare stock with a market cap of $1.20B. The stock last traded around $15.01 and up 0.9% across the available one-year price window (Jun 23, 2025 → Jul 21, 2025). Baseline metrics include revenue growth of +10.4%, EPS growth of +975.8%, a dividend yield of 0.0%. What stands out right now is revenue +10.4%, EPS +975.8%, free cash flow +26.4% with operating margin 16.9% and ROIC 3.8%. Valuation already assumes a fairly strong business story at P/E 70.3 and price/sales 11.9. Stock Foundry combines BITGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BITGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BITGF Max Drawdown
-0.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BITGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.1B
-11.4% YoY
FY Net Income
$175.0M
-14.6% YoY
Free Cash Flow
$218.0M
-26.6% YoY
Revenue Growth
+10.4%
EPS Growth
+975.8%
Gross Margin
62.3%
Net Margin
16.9%
Income statement
SEK
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Revenue | 2.1B | 1.9B | 1.6B | 1.2B | 1.1B |
| Gross Profit | 1.3B | 1.1B | 948M | 755M | 667M |
| Operating Income | 383M | 314M | 327M | 271M | 206M |
| EBITDA | 530M | 465M | 454M | 347M | 300M |
| Net Income | 284M | 246M | 268M | 205M | 175M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
SEK
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Cash & Equivalents | 434M | 594M | 441M | 311M | 371M |
| Total Assets | 5.1B | 4.9B | 2.3B | 2.0B | 1.4B |
| Total Liabilities | 991M | 1.3B | 702M | 621M | 444M |
| Shareholder Equity | 4.1B | 3.7B | 1.6B | 1.4B | 990M |
| Total Debt | 250M | 259M | 217M | 203M | 162M |
| Net Debt | -184M | -335M | -224M | -108M | -209M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
279M
-21.0% YoY
Capital Expenditures
61M
-8.9% YoY
Free Cash Flow
218M
-26.6% YoY
Key ratios
Gross Margin
62.3%
Operating Margin
16.9%
Net Margin
16.9%
ROE
4.1%
Debt / Equity
0.06x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.